Targeted therapy for advanced NSCLC: two steps forward and one step back?


Year:

Session type:

Frances Shepherd

Princess Margaret Hospital, Toronto, Canada

Abstract

Molecularly targeted therapy is an area of active investigation in treatment of non-small cell lung cancer (NSCLC). However, the past decade has seen the approval of only two classes of agents inhibitors of the epidermal growth factor receptor (EGFR) and inhibitors of angiogenesis.

I willdiscuss why drug trials targeting the EGFR pathway and angiogenesis are exciting and attractive areas in the treatment of lung cancer, highlighting why the results of these trials are eagerly awaited. Further work will, however, be required to identify the sub-groups of patients most likely to benefit from these drugs.